Table I.

Subject demographics, risk group, and baseline laboratory data

SubjectHIV-1 subtypeGeographic locationGenderRisk groupSampling dateVLClinical specimenEIAWBFiebig stagea
WITO4160BAlabamaMHeterosexual08.04.00325,064PlasmanegnegII
SUMA0874BAlabamaMMSM05.13.91939,260PlasmanegnegII
WEAU0575BAlabamaMMSM05.30.90216,415PlasmanegnegII
TRJO4551BAlabamaMMSM10.10.018,121,951PlasmanegnegII
04013226-2BNew YorkMMSM11.20.0226,700,000PlasmanegnegII
04013396-0BNew YorkMMSM08.16.051,600,000PlasmaposindIV
CH40 (700010040)BNorth CarolinaMMSM07.11.062,197,248SerumnegnegII
CH40 (700010040)07.27.06298,026Plasmapospos (p31)V
CH58 (700010058)BNorth CarolinaMMSM08.22.0692,581SerumnegnegII
CH58 (700010058)08.31.06394,649PlasmaposnegIII
CH77 (700010077)BNorth CarolinaMMSM08.25.063,565,728SerumnegnegII
CH77 (700010077)09.08.06144,145Plasmapospos (p31)V
ZM246FCZambiaFHeterosexual01.14.0310,013,800PlasmanegnegII
ZM249MCZambiaMHeterosexual08.05.03>2,000,000PlasmaposindIV
ZM247FCZambiaFHeterosexual10.28.0310,823,500PlasmanegnegII
  • EIA, enzyme-linked immunosorbant assay for HIV-1; ind, indeterminant; MSM, men who have sex with mena; VL, viral load (RNA molecules/ml); WB, Western blot for HIV-1.

  • a Fiebig clinical serological staging system (17).